Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 679 Avalo Therapeutics, Inc. shares (Form 4)

Traded Aug 10, 2026 · Filed Aug 12, 2026

On Aug 10, 2026, Doyle Mittie (Chief Medical Officer) sold 679 Avalo Therapeutics, Inc. shares at US$20.00 for US$13,580 under a trading plan, leaving 51,776 shares. Filed Aug 12, 2026 (Form 4).

Sold
679 shares
Price
US$20.00
Value
US$13,580
Holding after
51,776 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Medical Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Aug 10, 2026Common StockOption exercise679US$8.0452,455Direct
Aug 10, 2026Common StockSale679US$20.0051,776Direct

Source

View original at SEC

Related